Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up

BACKGROUND. Favorable progression‐free survival (PFS) and overall survival (OS) results were previously reported on a phase II trial of patients with human epidermal growth receptor 2 (HER2)‐positive metastatic breast cancer (MBC), treated with weekly paclitaxel in combination with trastuzumab and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Wang, Rui, Smyth, Lillian M., Iyengar, Neil, Chandarlapaty, Sarat, Modi, Shanu, Jochelson, Maxine, Patil, Sujata, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693713/
https://ncbi.nlm.nih.gov/pubmed/30602614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0512
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars